Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Teleflex Inc (NYSE:TFX). stock reached a new 52-week low, trading at $115.77. According to InvestingPro analysis, the medical technology company, currently valued at $5.1 billion, appears undervalued at these levels. This milestone reflects a significant decline for the company, which has experienced a 47.05% decrease over the past year. Despite the challenges faced amid market volatility and sector-specific pressures, the company maintains strong fundamentals with a healthy current ratio of 2.28 and an impressive 49-year track record of consistent dividend payments. InvestingPro subscribers can access 8 additional key insights about Teleflex’s financial health and growth prospects. Investors will be closely monitoring Teleflex’s strategic responses and market conditions as the company navigates this downturn, with particular attention to the upcoming earnings report in 10 days. Wall Street analysts maintain a positive outlook, with price targets suggesting potential upside of 25% from current levels.
In other recent news, Teleflex Incorporated has completed its acquisition of BIOTRONIK’s Vascular Intervention business for €760 million. This acquisition enhances Teleflex’s interventional access offerings and establishes a stronger presence in the peripheral intervention market. The company expects the newly acquired products to generate €177 million in revenue in the second half of 2025 and anticipates annual revenue growth of at least 6% starting in 2026. Additionally, the transaction is projected to add approximately $0.10 to Teleflex’s adjusted earnings per share in the first year.
Teleflex reported its Q1 2025 earnings, revealing a slight miss on both earnings per share and revenue forecasts. The company posted an EPS of $2.91, below the projected $2.95, and revenue of $700.7 million, missing the forecasted $705.99 million. Despite these shortfalls, Teleflex is actively exploring tariff mitigation strategies and has completed a $300 million share repurchase program. Needham has maintained a Hold rating on Teleflex stock following the Biotronik acquisition, raising its revenue and EPS estimates for 2025 and 2026. The firm noted that the planned separation into two businesses could provide greater visibility into revenue growth rates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.